µ²¸`©ÊÄo¯l¹ïÂå®v¨Ó»¡¤]¬O¬Û·í´Æ¤âªº¯e¯f¡A¹L¥h¨S¦³²z·Q®Úªvªº¤èªk¡A¦h¥H§Ü²Õ´Ói¡BÃþ©T¾Jµ¥ÃĪ«±±¨î¡CÀHµÛÂå¾Ç¬ì§Þªº¶i¨B¡AÁöµM¤w¦³¥Íª«»s¾¯¡B¼Ð¹vÃĪ«µ¥¥i¥Î©óªvÀø²§¦ì©Ê¥Ö½§ª¢¡A¦ý«o¨S¦³¥ô¦ó¤@¶µÃĪ«³Q»{¥iªvÀøµ²¸`©ÊÄo¯l¡C
¤£¹L¡Aªñ¤é¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^«Å¥¬¡A®Öã§ùÁת¢¡]Dupilumab¡^¥Íª«»s¾¯¥Î©óªvÀø¦¨¤Hµ²¸`©ÊÄo¯l¡A³o¤]¬OFDA²Ä¤@Ó§åã¨Ï¥Î©óµ²¸`©ÊÄo¯lªºªvÀø¤è¦¡¡C
®Ú¾Ú¬ü°ê°ê®a½Ã¥Í¬ã¨s°|¡]NIH¡^¤Wµo¥¬ªº¨â¶µÁ{§É¸ÕÅç¡Aµû¦ô§ùÁת¢¡]Dupilumab¡^ªvÀøµ²¸`©ÊÄo¯l¦³®Ä©Ê«á¡A»{¬°¨äªvÀø§ïµ½®ÄªG¨ã¦³ÅãµÛ©Ê¡C
¦Ó2020¦~¤]¦³¨t²Î©Ê¦^ÅU¬ã¨s¡A°w¹ï11½g¤å³¹¤¤¨Ï¥Î§ùÁת¢¡]Dupilumab¡^ªºµ²¸`©ÊÄo¯l±wªÌ¼Æ¾Ú¶i¦æ¤ÀªR¡A³q¹L¼Æ¦rµ¥¯Å¶qªí¡]NRS¡^µû¦ô·kÄo¯gªº§ïµ½µ{«×¡A¨ä¤¤¦³82.22%ªº±wªÌªí¥Ü·kÄo±¡ªp´î¥b¡A¦³48.88%ªº±wªÌ·kÄo±¡§Î§¹¥þ½w¸Ñ¡A¦ý¶·ªvÀø4Ó¤ë¥H¤W¡C
«À©vªNÂå®vªí¥Ü¡Aªñ´X¦~Á{§É¸gÅç¤]µo²{¡A¼Æ¨ÒÄY«²§¦ì©Ê¥Ö½§ª¢¨Öµoµ²¸`©ÊÄo¯lªº¯fµ£¡A¸g¹L§ùÁת¢ªvÀø4¦Ü6Ӥ뤧«á¡A°£¤F²§¦ì©Ê¥Ö½§ª¢ªº¥Ö¯l¤j´T§ïµ½¡AÁÙ·N¥~µo²{µ²¸`©ÊÄo¯l¥i¯à¤]¦³ªvÀø®ÄªG¡A±wªÌ¬ð°_ªºµ²¸`ÅÜ¥¡A·kÄo¤]´î½w¡C
¤£¹L¡A§ùÁת¢¹ï18·³¥H¤Uªºµ²¸`©ÊÄo¯l±wªÌ¬O§_¦w¥þ¦³®Ä©|¤£²M·¡¡A¦Ó¥B·|¦³ª`®g³¡¦ì¯kµh¡B¦Ù¦×¯kµh¡B¸¡Âmµ¥±`¨£°Æ§@¥Î¡A¬Æ¦Ü¥i¯à·|¦³¹L±Ó¡BÃö¸`µh¡BÃö¸`ª¢¡B¦åºÞª¢µ¥ÄY«°Æ§@¥Î¡C
¦ý«À©vªNÂå®v´£¨ì¡A¹L¥h¤£¥u¥Íª«»s¾¯¨S¦³µ²¸`©ÊÄo¯l¾AÀ³¯g¡A¤]¨S¦³¥ô¦ó¨ä¥LªºÃĪ«³Q¬ü°êFDA»{¥iªvÀøµ²¸`©ÊÄo¯l¡A³o¦¸§ùÁת¢³QFDA®Öã¡A¹L¥h´Æ¤âªºµ²¸`©ÊÄo¯l²×©ó¦³¤F²Ä¤@ºØ¦w¥þ¦³®ÄªºªvÀøÃĪ«³Q»{¥i¡A³o¥i¿×¯f±wªººÖµ¡A¤]¬Oµ²¸`©ÊÄo¯lªvÀøªº¤j¶i®i¡C
¸ê®Æ¨Ó·½¡G
https://m.facebook.com/story.php?story_fbid=pfbid02tyYohzpi4eP5T9gQNSrKrt3rfmv7SH7BGokWyLbeUtbPs6Hh4wQFL7D2Yaoq5R3fl&id=100057449259384&mibextid=qC1gEa
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-prurigo-nodularis
¥»¤å¸g °·±dÂåÀøºô ±ÂÅv¥Zµn¡Aì¤åµoªí
©ó¦¹
¡i°·±dÂåÀøºô¡þ°OªÌ§d»ö¤å³ø¾É¡j2023/04/20